Table 1

Therapeutic agents targeting components of the type I IFN pathway and in clinical development for IFN-driven diseases

Drug	Drug MOA	Development status	Disease
RSLV132	RNA hydrolysis	Phase II	Systemic lupus erythematosus Sjögren's syndrome
SM101	Anti–immune complex	Phase II	Systemic lupus erythematosus Lupus nephritis
BIIB059	Anti-BDCA2 (pDCs)	Phase II	Systemic lupus erythematosus
MEDI-7734	Anti-ILT7 (pDCs)	Phase I	Dermatomyositis Polymyositis Systemic sclerosis Sjögren's syndrome Systemic lupus erythematosus
JNJ-55920839	Anti–IFN-α/ω	Phase I	Systemic lupus erythematosus
AGS-009	Anti–IFN-α	Phase I*	Systemic lupus erythematosus
IFN-α-kinoid	Anti–IFN-α	Phase II	Dermatomyositis
IFN-α-kinoid	Anti–IFN-α	Phase II	Systemic lupus erythematosus
Anifrolumab	Anti-IFNAR1	Phase II	Lupus nephritis
Anifrolumab	Anti-IFNAR1	Phase III	Systemic lupus erythematosus
Baricitinib†	JAK1/JAK2 inhibitor	Phase II	Systemic lupus erythematosus
PF-04965842	JAK1 inhibitor	Phase II	Systemic lupus erythematosus

*Development status unknown.
†European Medicines Agency approved for rheumatoid arthritis.
IFN, interferon; IFNAR1, type I interferon alpha receptor subunit 1; ILT7, immunoglobulin-like transcript 7; JAK, Janus kinase; MOA, mechanism of action; pDCs, plasmacytoid dendritic cell.